Strides Pharma Science Ltd Technical Momentum Shifts Amid Mixed Indicator Signals

Technical Trend Overview and Price Momentum

Strides Pharma Science Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, currently trades at ₹1,200.05, up from the previous close of ₹1,188.55. The stock’s 52-week high stands at ₹1,231.45, while the low is ₹769.60, indicating a strong recovery and upward price momentum over the past year. The daily trading range today has been between ₹1,161.20 and ₹1,213.30, reflecting moderate volatility.

The technical trend has shifted from bullish to mildly bullish, signalling a potential deceleration in upward momentum. This subtle change suggests that while the stock remains in an overall positive trend, investors should be alert to possible consolidation or minor pullbacks in the near term.

MACD and RSI: Divergent Signals

The Moving Average Convergence Divergence (MACD) indicator remains bullish on both weekly and monthly timeframes, reinforcing the presence of positive momentum. The weekly MACD continues to show a strong upward trajectory, supporting the stock’s recent gains. Similarly, the monthly MACD confirms sustained buying interest over a longer horizon.

Conversely, the Relative Strength Index (RSI) presents a mixed scenario. On the weekly chart, the RSI is neutral, offering no clear signal of overbought or oversold conditions. However, the monthly RSI is bearish, indicating that the stock may be approaching overbought territory or facing downward pressure in the medium term. This divergence between MACD and RSI suggests that while momentum remains intact, caution is warranted as the stock could experience a technical correction.

Moving Averages and Bollinger Bands Confirm Bullish Bias

Daily moving averages continue to support a bullish outlook, with the stock price trading above key averages such as the 50-day and 200-day moving averages. This alignment typically signals sustained upward momentum and investor confidence.

Bollinger Bands on both weekly and monthly charts are also bullish, indicating that price volatility is contained within an upward trending channel. The bands suggest that the stock has room to move higher without immediate risk of a sharp reversal, although the narrowing of bands could hint at an impending volatility expansion.

Other Technical Indicators: KST, Dow Theory, and OBV

The Know Sure Thing (KST) indicator shows a mildly bearish signal on both weekly and monthly timeframes, suggesting some weakening in momentum. This contrasts with the MACD’s bullish stance and highlights the complexity of the current technical environment.

Dow Theory analysis reveals no clear trend on the weekly chart, while the monthly chart is mildly bearish. This indicates that the broader market sentiment for Strides Pharma is somewhat cautious, with potential for sideways movement or minor declines in the near term.

On-Balance Volume (OBV) presents a mixed picture as well. The weekly OBV shows no definitive trend, whereas the monthly OBV remains bullish, implying that longer-term accumulation by investors is still ongoing despite short-term fluctuations.

Comparative Performance: Strides Pharma vs Sensex

Strides Pharma has outperformed the Sensex significantly across multiple time horizons. Over the past week, the stock declined by 1.45%, slightly underperforming the Sensex’s 0.79% drop. However, over one month, Strides Pharma surged 21.58%, while the Sensex fell 4.39%. Year-to-date returns for the stock stand at an impressive 32.99%, compared to a negative 12.80% for the Sensex.

Longer-term performance is even more striking. Over one year, Strides Pharma gained 35.61%, while the Sensex declined 10.13%. Over three years, the stock’s return is a remarkable 430.97%, dwarfing the Sensex’s 9.55%. Even over five and ten years, Strides Pharma’s returns of 330.82% and 176.99% respectively far exceed the Sensex’s 25.92% and 159.85% gains.

This outperformance underscores the company’s strong growth trajectory and resilience amid broader market volatility.

Mojo Score and Rating Revision

MarketsMOJO has recently revised Strides Pharma’s Mojo Grade from Buy to Hold as of 15 September 2026, reflecting the evolving technical landscape. The current Mojo Score stands at 64.0, indicating moderate confidence in the stock’s near-term prospects. This downgrade aligns with the mixed technical signals and the shift to a mildly bullish trend, suggesting investors should adopt a more cautious stance.

The small-cap designation further emphasises the stock’s higher volatility and risk profile compared to larger pharmaceutical peers.

Investor Takeaway and Outlook

Strides Pharma Science Ltd’s technical parameters reveal a stock in transition. While the bullish MACD, moving averages, and Bollinger Bands support continued upward momentum, bearish signals from the monthly RSI, KST, and Dow Theory counsel prudence. The mildly bullish trend suggests that the stock may consolidate or experience minor pullbacks before resuming a stronger uptrend.

Investors should monitor key support levels near the daily moving averages and watch for confirmation from volume-based indicators such as OBV. Given the recent Mojo Grade downgrade to Hold, a balanced approach is advisable, favouring partial exposure rather than aggressive accumulation.

Comparative returns versus the Sensex highlight Strides Pharma’s robust long-term growth, but the current technical signals imply that short-term volatility may increase. Those with a higher risk tolerance may view dips as buying opportunities, while more conservative investors might await clearer bullish confirmation.

Overall, Strides Pharma remains a noteworthy contender in the Pharmaceuticals & Biotechnology sector, but the mixed technical landscape calls for careful analysis and disciplined risk management.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today